Daily News Podcast

Rivaroxaban data abound at ESC 2018

Publish date: August 28, 2018

 

New results from the ASCEND trial show that neither aspirin nor fish oil provides any net clinical benefit for primary cardiovascular prevention in patients with diabetes. Also today, rivaroxaban is no help for heart failure outcomes, VTE risk is unchanged by rivaroxaban taken after discharge, and the AAP cautions against marijuana use during pregnancy and breastfeeding. Subscribe to the MDedge Daily News wherever you get your podcasts.

Amazon Alexa
Apple Podcasts
Spotify

Recommended Reading

Prolonged antimalarial therapy linked to elevated cardiac biomarkers, cardiomyopathy
MDedge Rheumatology
Medicare Advantage pushback
MDedge Rheumatology
Psoriasis registry study provides more data on infliximab’s infection risk
MDedge Rheumatology
Cardiovascular risk management supported for type 2 diabetes
MDedge Rheumatology
An epidemic of non-alcoholic fatty liver disease
MDedge Rheumatology
Sleepio app tied to reducing insomnia, depression
MDedge Rheumatology
5 digital HIPAA myths
MDedge Rheumatology
Screen for cervical cancer based on age, risk
MDedge Rheumatology
Is it time for PCPs to take over chronic HCV?
MDedge Rheumatology
Lorcaserin shows cardiovascular safety
MDedge Rheumatology